Janux Therapeutics
JANX • NASDAQ
Janux Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO David Alan Campbell, with a market cap of $807.2M.
CEODavid Alan Campbell
Market Cap$807.2M
Biotechnology
Healthcare
Employees68.0
Websitejanuxrx.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Janux Therapeutics
Date
Thursday, May 7, 2026 (in 2 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.61
Revenue Estimate
$4.0M
Earnings History
Past 12 earnings reports for Janux Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Q4 2025 | -$0.51Est: -$0.64 | +20.3% | -Est: $71.4K | -100.0% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.39Est: -$0.61 | +36.1% | $10.0MEst: $5.0M | +101.3% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.55Est: -$0.47 | -17.0% | -Est: $272.7K | -100.0% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.38Est: -$0.39 | +2.6% | -Est: $650.0K | -100.0% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.36Est: -$0.45 | +20.0% | -Est: $490.0K | -100.0% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.51Est: -$0.33 | -54.5% | $439.0KEst: $1.6M | -73.2% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.11Est: -$0.31 | +64.5% | $8.9MEst: $767.4K | +1059.3% | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.30Est: -$0.33 | +9.1% | $1.3MEst: $760.0K | +64.7% | 10-Q |
| Mar 8, 2024 | Q4 2023 | -$0.25Est: -$0.40 | +37.5% | $2.5MEst: $750.0K | +228.1% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.25Est: -$0.47 | +46.8% | $2.5MEst: $850.0K | +196.1% | — |
| Aug 8, 2023 | Q2 2023 | -$0.42Est: -$0.52 | +19.2% | $1.1MEst: $870.0K | +21.5% | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.42Est: -$0.49 | +14.3% | $2.0MEst: $670.0K | +205.7% | — |